J
Jordi Bové
Researcher at Columbia University
Publications - 30
Citations - 4604
Jordi Bové is an academic researcher from Columbia University. The author has contributed to research in topics: Neurodegeneration & Substantia nigra. The author has an hindex of 21, co-authored 29 publications receiving 3943 citations.
Papers
More filters
Journal ArticleDOI
Toxin-Induced Models of Parkinson's Disease
TL;DR: What the authors believe are the four most popular parkinsonian neurotoxins, namely 6-hydroxydopamine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, rotenone, and paraquat are discussed.
Journal ArticleDOI
Pathogenic Lysosomal Depletion in Parkinson's Disease
Benjamin Dehay,Jordi Bové,Natalia Rodriguez-Muela,Celine Perier,Ariadna Recasens,Patricia Boya,Miquel Vila +6 more
TL;DR: It is found in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of PD that AP accumulation and dopaminergic cell death are preceded by a marked decrease in the amount of lysosomes within dopamine neurons, indicating that restoration of lYSosomal levels and function may represent a novel neuroprotective strategy in PD.
Journal ArticleDOI
Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys
Ariadna Recasens,Benjamin Dehay,Jordi Bové,Iria Carballo-Carbajal,Sandra Dovero,Ana Perez-Villalba,Pierre-Olivier Fernagut,Javier Blesa,Annabelle Parent,Celine Perier,Isabel Fariñas,Jose A. Obeso,Erwan Bezard,Miquel Vila,Miquel Vila +14 more
TL;DR: Supporting this concept, intracerebral inoculation of synthetic recombinant α‐synuclein fibrils can trigger α‐Synuclein pathology in mice, and it remains uncertain whether the pathogenic effects of recombinant synthetic α‐ synuclein may apply to PD‐linked pathological α‐ Synuclein and occur in species closer to humans.
Journal ArticleDOI
Fighting neurodegeneration with rapamycin: mechanistic insights
TL;DR: The molecular mechanisms underlying the neuroprotective effects of rapamycin are reviewed and the therapeutic potential of this compound for neurodegenerative diseases is discussed.
Journal ArticleDOI
Neurotoxin-based models of Parkinson's disease.
Jordi Bové,Celine Perier +1 more
TL;DR: How epidemiological data may help to validate a specific model with data linking a lower risk of developing PD with nutritional/consumption habits or with a specific chronic drug therapy is discussed.